J&J Duragesic Pediatric Exclusivity Keeps Mylan Fentanyl Patch Off The Market Until January

FDA rejects Mylan's argument linking pediatric exclusivity with the 30-month stay. Mylan says it will sue FDA to restore final approval of its ANDA, which is now deemed tentatively approved.